World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 30 May 2022
Main ID:  EUCTR2019-002810-37-LT
Date of registration: 03/03/2020
Prospective Registration: Yes
Primary sponsor: Dr. Reddy’s Laboratories S.A.
Public title: A study to assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
Scientific title: A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
Date of first enrolment: 17/04/2020
Target sample size: 140
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002810-37
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Bulgaria Czechia Germany Hungary Lithuania Poland United States
Contacts
Name: Narendra Maharaj   
Address:  Biologics, Survey No. 47, Bachupally Village, Bachupally Mandal 500 090 Medchal Malkajgiri District, Telangana India
Telephone: +9104044644000
Email: narendramaharaj@drreddys.com
Affiliation:  Dr. Reddy’s Laboratories Ltd.
Name: Narendra Maharaj   
Address:  Biologics, Survey No. 47, Bachupally Village, Bachupally Mandal 500 090 Medchal Malkajgiri District, Telangana India
Telephone: +9104044644000
Email: narendramaharaj@drreddys.com
Affiliation:  Dr. Reddy’s Laboratories Ltd.
Key inclusion & exclusion criteria
Inclusion criteria:
1. Male or female subjects aged 18 years or older who have provided valid written informed consent.
2. Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US rituximab or EU rituximab according to the clinical judgment of the investigator.
3. Documented evidence that subject has received at least 1 full course comprising two 1000 mg infusions of either US rituximab at least 16 weeks prior to the randomization visit or EU rituximab at least 24 weeks prior to the day of randomization visit.
Note: Subjects are only eligible if they have received the prior US or EU-rituximab course within the 15 months prior to the date of randomization.
4. Subjects receiving a stable dose of weekly MTX for at least 4 weeks prior to randomization (between 7.5 mg and 25 mg) and folic acid (at least 5 mg per week).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 120
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion criteria:
1. Subjects with RA in functional Class IV
2. Subjects with human immunodeficiency virus (positive HIV1Ab or HIV2Ab), hepatitis B virus and/or hepatitis C virus infection, including those with positive results in the viral disease screening
3. Subjects with active tuberculosis (TB). Subjects with evidence of latent TB or a history of TB must have completed treatment or have initiated treatment for at least 1 month before the first dose of study treatment (Day 1). TB testing is required only if it is required by local regulations or practice.
4. Active systemic infection.
5. Severely immunocompromised.
6. History of hypersensitivity to either US rituximab or EU rituximab or any of its excipients.
7. Any serious illness or uncontrolled medical condition, including, but not limited to, severe infections, significant hepatic or renal disease, uncontrolled hypertension despite treatment (defined as blood pressure [BP] =160/95 mmHg), congestive heart failure (New York Heart Association [NYHA] Class III or IV), or other severe uncontrolled cardiac disease or uncontrolled diabetes with immediate risk of acute complications.
8. Any condition that in the opinion of the investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects.
9. Requires treatment with any biological medicinal product during the study other than the study treatment.
10. Previous treatment with B-cell modulating or cell depleting biologic therapy, except US rituximab or EU rituximab.
11. Prior participation in this clinical trial or prior participation in any clinical trial with any monoclonal antibody within 12 months of screening or prior participation in any clinical trial within 3 months of screening or within 5 half-lives of the investigational drug or until the expected PD effect has returned to baseline, whichever is longer.
12. Treatment with other biologic DMARDs, or Janus kinase (JAK) inhibitors administered within 12 weeks before the first dose of rituximab of the prior treatment course onwards till the date of randomization.
13. Subjects with the following laboratory abnormalities:
• Subjects with screening total white blood cell count <3000/µL, platelets <100,000/µL, neutrophils <1500/µL, or hemoglobin <8.5 g/dL.
• Abnormal liver function tests such as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase >2 × upper limit of normal (ULN). A single parameter >2 × ULN can be re-checked as soon as possible, at least prior to randomization, if required as per the investigator’s discretion.
• Creatinine clearance (Cockcroft & Gault formula) of less than 50 mL/min.
14. History of vaccination with live vaccines within 4 weeks of the first dose of study treatment (Day 1) or known to require live vaccines during the study.
15. Lactating or pregnant female.
16. Women of childbearing potential who do not consent to use highly effective methods of birth control during treatment and for at least 12 months after the last administration of study treatment.
Note: Per the Clinical Trial Facilitation Group (CTFG) guidelines 2014, a woman is considered of childbearing potential if fertile, following menarche until becoming postmenopausal (i.e., no menses for 12 months without an alternative medical cause) unless permanently sterile through hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). Highly effective birth control measures per CTFG guidelines 2014 include the foll


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Rheumatoid Arthritis
MedDRA version: 23.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Intervention(s)

Trade Name: Reditux
Product Name: Dr. Reddy’s Rituximab (DRL_RI) 100mg
Product Code: DRL_RI
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-

Trade Name: MabThera
Product Name: MabThera 100mg
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-

Trade Name: Reditux
Product Name: Dr. Reddy’s Rituximab (DRL_RI) 500mg
Product Code: DRL_RI
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-

Trade Name: MabThera
Product Name: MabThera 500mg
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-

Primary Outcome(s)
Timepoint(s) of evaluation of this end point: • Samples for detection of ADA will be collected at Weeks 4, 8, and 12 (EOS/ET visit).
• Samples for detection of NAB will be collected at Weeks 4, 8, and 12 (EOS/ET visit).

• Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) - on occurrence.
• Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs - on occurrence.

• Clinical laboratory assessments, vital signs measurement and Physical examination will be performed at the screening, on Day 1, Day 15, and at Weeks 4, 8, and 12 (EOS/ET) visits.
• Twelve-lead electrocardiogram (ECG) - at the screening and End of Treatment.
Main Objective: To assess the immunogenicity of transitioning subjects with RA to DRL_RI (biosimilar rituximab) from US rituximab/EU rituximab to continued treatment with US rituximab/EU rituximab.

To assess the safety of transitioning subjects with RA to DRL_RI from US rituximab/EU rituximab to continued treatment with US rituximab/EU rituximab.
Primary end point(s): The immunogenicity endpoint is:
• The incidence of anti-drug antibodies (ADA), including titer and neutralizing antibodies (NAb).

The primary safety endpoints are:
• Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
• Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs.

Other safety endpoints are:
• Clinical laboratory parameters
• Vital signs
• Twelve-lead electrocardiogram (ECG)
• Physical examination
Secondary Objective: None
Secondary Outcome(s)
Secondary end point(s): None
Timepoint(s) of evaluation of this end point: None
Secondary ID(s)
2019-002810-37-HU
RI-01-007
Source(s) of Monetary Support
Dr. Reddy’s Laboratories S.A.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 01/04/2020
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey